Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
118/433 Publications
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
-
Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Review
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
-
Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.
-
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
-
Non-invasive diagnosis and follow-up of portal hypertension.
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
-
Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
-
The non-invasive assessment of hepatic fibrosis.
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
-
Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
-
Glycogenic hepatopathy.
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
-
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
-
A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
-
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
-
Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
-
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis.
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
-
Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.
-
Noninvasive evaluation of NAFLD.
-
Silymarin in non alcoholic fatty liver disease.
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
-
Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.
-
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
-
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
-
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
-
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
-
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
-
[The prevalence of liver and gallbladder pathologies in overweight and obese patients].
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Non-invasive markers for hepatic fibrosis.
-
Noninvasive assessment of portal hypertension in patients with cirrhosis.
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
-
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
-
Non-invasive assessment of liver fibrosis: are we ready?
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
-
Applicability and variability of liver stiffness measurements according to probe position.
-
Liver biopsy: the best standard...when everything else fails.
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
-
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
-
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
-
Assessment of liver fibrosis: noninvasive means.
-
Biomarkers of liver fibrosis.
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
-
FibroMAX: towards a new universal biomarker of liver disease?
-
Guidelines for the diagnosis of uncomplicated cirrhosis.
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
-
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
-
La Haute Autorite de Sante (HAS) in France— Diagnosis of uncomplicated cirrhosis (Accessed December 2011)
Showing the full result list. The page is server-rendered and not paginated.